Webinars

Developability is an increasingly critical concept in antibody discovery and development. Previously associated with late-stage outcomes such as stability and formulation, developability assessment is now integrated earlier in the discovery process to enable multidimensional profiling of lead candidates.

WhenThursday, October 16, 2025 · 11:00 a.m.Eastern Time (US & Canada) (GMT -4:00)Register here >>AboutSuccessful antibody discovery requires more than just access to powerful platforms - it demands the experience to apply them efficiently and strategically.In this webinar, we

Biointron’s Lunch & Learn with KACTUS was held at CIC Cambridge, MA on September 12. The session featured three key speakers: Sagar Kathuria, PhD (Senior Principal Scientist at Sanofi), Alexander Hostetler, PhD (Application Scientist at KACTUS Biosystems), and Gang Liu, PhD (Director of Discovery Services at Biointron). We thoroughly enjoyed hosting the event and the audience’s strong engagement!

Watch a recording of Biointron’s Lunch & Learn with MassBio from May 9, 2025. The session focused on the advancements in antibody discovery in the biopharma industry and featured three key speakers.

In this webinar, Dr. Brady Wu will discuss bispecific antibody drugs and their production.

Biointron is thrilled to collaborate with Carterra to bring you an exclusive live webinar: Innovative Methods Advancing Discovery and Characterization of Antibodies

Biointron is excited to announce our upcoming collaborative webinar with the Antibody Society, scheduled for June 26th, 2025. This webinar will feature our speaker, Dr. Gang Liu, Associate Director of Biointron. Dr. Liu will delve into the captivating topic of "AbDrop Speeds: Accelerating Your Antibody Discovery with Single B Solution," providing attendees with a rich and informative exploration of the latest trends and advancements in antibody discovery technologies.

Lei Shi, PhD, Senior Vice President of Biointron, discusses: "Simplified and Humanized: Empowering Human Antibody Discovery with AbDrop™ Solution" during the Antibody Engineering & Therapeutics US 2024 conference in San Diego.

Biointron has established an industry-leading 2-week antibody production service, supported by a powerful high-throughput expression platform.

This topic explores the revolutionary potential of the genome-edited mouse HUGO-Ab, where endogenous VH and VL genes are replaced by fully human VH and VL genes in situ, enabling the generation of fully human antibody molecules.

Biointron's SVP of R&D, Lei Shi, PhD, discussed the processes of accelerating early discovery through HTP and high-speed antibody production during the Antibody Engineering & Therapeutics US 2023 conference in San Diego. Below is a summary of the talk.

Talk Title: Innovative Multiple Tech & Platforms Empower Antibody DiscoverySpeaker: Dr.Long Xu, Director, R&D Strategy at BiointronBiointron is excited to announce our upcoming collaborative webinar with the Antibody Society, scheduled for September 26th, 2023. This webinar will featur

Talk Title: Innovative Multiple Tech & Platforms Empower Antibody DiscoverySpeaker: Dr.Long Xu, Director, R&D at BiointronBiointron is thrilled to announce our upcoming collaborative webinar with the Chinese Antibody Society, set to take place on September 16th from 9-10 PM EST (Septem

Together with the Chinese Antibody Society, Biointron's latest webinar features Shun Zhou, Ph.D, the R&D Director at Cyagen: “Accelerating Antibody Discovery with Fully Human Antibody Mouse HUGO-Ab™ and Single B Cell Screening Technology AbDrop™”